A retrospective review of data from the National Cancer Data Base demonstrated that trends in rectal cancer may follow a pattern similar to that of colon cancer.
A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.
In a prospective, longitudinal study, researchers investigated the potential for quality of life, fatigue, and physical functioning to return to previous levels in patients with AML after treatment.
Researchers explored connections between overall survival and adjuvant radiotherapy when factoring in CTC status.
Latest findings do not confirm an overall survival (OS) benefit found in a previous randomized phase 2 trial.
The addition of mitoxantrone and prednisone (MP) to adjuvant androgen-deprivation therapy did not increase survival among patients with high-risk prostate cancer.
Long-term analysis determined the effect of postadjuvant dose-dense chemotherapy on DLCO among women with breast cancer.
A phase 2 study determined if adding bevacizumab or temsirolimus to PC, or an ixabepilone/carboplatin/bevacizumab combination will increase progression-free survival for women with advanced/recurrent endometrial cancer, compared with PC alone.
In a follow-up to the Women's Health Initiative study, researchers determined the effect of a low-fat diet on overall survival after a breast cancer diagnosis.
Researchers conducted a retrospective cohort analysis to examine patterns of clinical practice in the management of women with advanced HGSC.
In this phase 2 study, researchers randomly assigned 79 patients with immunotherapy-naive melanoma with brain metastases to receive either nivolumab plus ipilimumab or nivolumab alone.
A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.
A group of Australian researchers report study findings that demonstrate a significant improvement in PFS in patients with relapsed/refractory CLL treated with venetoclax plus rituximab compared with the standard care.
Researchers evaluated survival in patients with colon cancer, according to the type of insurance the patients held.
A report on how variations in the effects of geriatric syndromes and aging can affect treatment modality choices and outcomes for the eldest older adults with hematologic cancers.
Venetoclax plus rituximab increases progression-free survival in relapsed chronic lymphocytic leukemiaMarch 31, 2018
1. Patients with relapsed or remitting chronic lymphocytic leukemia (CLL) treated with venetoclax-rituximab had a greater 2-year progression-free survival rate compared to bendamustine-rituximab treated patients. 2. Progression-free survival rates were greater for venetoclax-rituximab patients in almost all subgroup analysis, including patients with chromosome 17p deletion. Evidence Rating Level: 1 (Excellent) Study Rundown: Curative treatment of relapsed 
A multivariable analysis revealed how median household income influences cancer-specific and overall survival among patients with squamous cell carcinoma of the anus.
A retrospective study evaluated the relationship of BMI with survival outcomes among patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.
SPARTAN phase 3 study shows that apalutamide prolongs metastasis-free survival and time to symptomatic progression compared with placebo among men with nonmetastatic CRPC.
Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.
Advances in breast cancer treatment are improving outcomes for patients with the disease; however, treatments are increasing these patients' risk for cardiovascular diseases.
In this study, researchers sought to determine the effect depressive symptoms during treatment planning had on immediate and long-term outcomes for patients with head and neck cancer.
In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.
Capecitabine and Oxaliplatin as First and Second Line Treatment for Locally Advanced and Metastatic Pancreatic Ductal AdenocarcinomaDecember 22, 2017
[Journal of Gastrointestinal Oncology] This research evaluates the use of capecitabine and oxaliplatin (CAPOX) for first or second-line treatment of locally advanced or metastatic PDAC.
In a retrospective study of SEER-Medicare data, researchers determined the survival outcomes of women with breast cancer and comorbid mental illness vs those without mental illness.
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
A comparison of adjuvant endocrine therapies showed one option provided greater reduction in disease recurrence among premenopausal women with ER+ breast cancer.
A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.
Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.
Lomustine plus bevacizumab may increase progression-free, but not overall, survival versus lomustine alone in progressive glioblastoma.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|